Search - tctmd.com

Displaying 681 - 700 of 752

Sort: Relevancy | Date

News Daily News

La Morfología del Apéndice Auricular Izquierdo Podría Ayudar a Predecir el Riesgo de ACV en Pacientes con FA

July 31, 2012

News Daily News

Anticoagulation Protects A-Fib Patients Undergoing PCI, Despite Bleeding Risk

Caitlin E. Cox

July 16, 2012

News Daily News

La Anticoagulación Protege a aquellos Pacientes con FA que se someten a PCI, a pesar del Riesgo Hemorrágico

Caitlin E. Cox

July 16, 2012

News Daily News

Apixaban Less Costly Than Aspirin for Stroke Prevention in A-Fib at 10 Years

Caitlin E. Cox

July 12, 2012

News Daily News

A los 10 Años el Apixaban resulta Más Barato que la Aspirina para la Prevención de ACV en Pacientes con FA

Caitlin E. Cox

July 12, 2012

Presentation

Cost-Effectiveness of Apixaban vs. Aspirin for Stroke Prevention Among A-fib Pts Unsuitable for Warfarin

Presenter: S. Lee

July 11, 2012

News Industry News

Boston Scientific Completes Patient Enrollment in PREVAIL Study for First-in-Class WATCHMAN Device

July 02, 2012

News Daily News

RE-LY: El Dabigatran Acorta la Interrupción del Fármaco sin Aumentar los Episodios Hemorrágicos

Jason Kahn

June 22, 2012

News Daily News

RE-LY: Dabigatran Shortens Drug Interruption with No Increased Bleeding

Jason Kahn

June 22, 2012

Presentation

Periprocedural Bleeding and Thromboembolic Events with Dabigatran Compared to Warfarin

Presenter: Jeff S. Healey

June 21, 2012

News Daily News

Door Still Not Shut on CLOSURE I

Yael L. Maxwell

June 15, 2012

News Daily News

Todavía No se ha Cerrado la Puerta del CLOSURE I

Yael L. Maxwell

June 15, 2012

News Daily News

Rivaroxaban May be Cost-Effective for A-fib Patients

L.A. McKeown

June 06, 2012

News Daily News

El Rivaroxaban podría ser Rentable en Pacientes con Fibrilación Auricular

L.A. McKeown

June 06, 2012

Presentation

Cost-effectiveness of Rivaroxaban Compared to Warfarin for Stroke Prevention in Atrial Fibrillation

Presenter: S. Lee

June 05, 2012

Presentation TVT 2012

The Watchman Clinical Studies Program (Warfarin Eligible): Perspectives, New Insights, and Future Directions

Presenter: Saibal Kar

June 05, 2012

Presentation TVT 2012

ASAP Results: The Watchman in Warfarin Ineligible Patients

Presenter: Shephal Doshi

June 05, 2012

News Daily News

Watchman Works Just as Well Without Warfarin-Protected Transition

June 01, 2012

News Daily News

El Watchman Funciona Igual de Bien sin Transición Protegida con Warfarina

June 01, 2012

News Industry News

Study of First-in-Class WATCHMAN® Device Shows 75 Percent Reduction in Stroke Risk in Patients with Atrial Fibrillation Not Eligible for Oral Anticoagulation Therapy

May 11, 2012

Advertisement

La Morfología del Apéndice Auricular Izquierdo Podría Ayudar a Predecir el Riesgo de ACV en Pacientes con FA

Anticoagulation Protects A-Fib Patients Undergoing PCI, Despite Bleeding Risk

La Anticoagulación Protege a aquellos Pacientes con FA que se someten a PCI, a pesar del Riesgo Hemorrágico

Apixaban Less Costly Than Aspirin for Stroke Prevention in A-Fib at 10 Years

A los 10 Años el Apixaban resulta Más Barato que la Aspirina para la Prevención de ACV en Pacientes con FA

Cost-Effectiveness of Apixaban vs. Aspirin for Stroke Prevention Among A-fib Pts Unsuitable for Warfarin

Boston Scientific Completes Patient Enrollment in PREVAIL Study for First-in-Class WATCHMAN Device

RE-LY: El Dabigatran Acorta la Interrupción del Fármaco sin Aumentar los Episodios Hemorrágicos

RE-LY: Dabigatran Shortens Drug Interruption with No Increased Bleeding

Periprocedural Bleeding and Thromboembolic Events with Dabigatran Compared to Warfarin

Door Still Not Shut on CLOSURE I

Todavía No se ha Cerrado la Puerta del CLOSURE I

Rivaroxaban May be Cost-Effective for A-fib Patients

El Rivaroxaban podría ser Rentable en Pacientes con Fibrilación Auricular

Cost-effectiveness of Rivaroxaban Compared to Warfarin for Stroke Prevention in Atrial Fibrillation

The Watchman Clinical Studies Program (Warfarin Eligible): Perspectives, New Insights, and Future Directions

ASAP Results: The Watchman in Warfarin Ineligible Patients

Watchman Works Just as Well Without Warfarin-Protected Transition

El Watchman Funciona Igual de Bien sin Transición Protegida con Warfarina

Study of First-in-Class WATCHMAN® Device Shows 75 Percent Reduction in Stroke Risk in Patients with Atrial Fibrillation Not Eligible for Oral Anticoagulation Therapy

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content